Impaired oxidation of pyruvate in human embryonic fibroblasts after exposure to L-dopa.
The effect of 3,4-dihydroxyphenylalanine (L-dopa) treatment on the ability of intact human cells to metabolize substrates for mitochondrial oxidative phosphorylation was studied in embryonic fibroblasts. Treatment with L-dopa (100-400 microM) for 48 h significantly reduced the oxidation of pyruvate but had no effect on succinate oxidation. The effect was dose-dependent and was still present 2 days after removal of L-dopa. Ascorbic acid (200 microM) protected the cells from the effects of L-dopa; ascorbate alone enhanced pyruvate but not succinate oxidation.
Werner
P
P
Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029.
Mytilineou
C
C
Cohen
G
G
Yahr
M D
MD
D001205:Ascorbic Acid / Q000494:pharmacology; D002478:Cells, Cultured; D005333:Fetus; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D010084:Oxidation-Reduction; D010085:Oxidative Phosphorylation / Q000187:drug effects*; D011773:Pyruvates / Q000378:metabolism*; D019289:Pyruvic Acid; D011837:Radiation-Protective Agents / Q000378:metabolism; D013386:Succinates / Q000378:metabolism; D019802:Succinic Acid
D011773:Pyruvates; D011837:Radiation-Protective Agents; D013386:Succinates; D007980:Levodopa; D019289:Pyruvic Acid; D019802:Succinic Acid; D001205:Ascorbic Acid